Table 3 Comparative analysis of medical therapy of patients, overall or according to β-blocker therapy.

From: Β-blockers treatment of cardiac surgery patients enhances isolation and improves phenotype of cardiosphere-derived cells

Drug*

Overall

No β-blocker therapy

Β-blocker therapy

P†

Angiotensinogen converting enzyme inhibitor

18/41 (43.9%)

9/19 (47.4%)

9/22 (40.9%)

0.758

Aldosterone receptor antagonist

8/41 (19.5%)

2/19 (10.5%)

6/22 (27.3%)

0.249

Angiotensin II receptor antagonist

12/41 (29.3%)

6/19 (31.6%)

6/22 (27.3%)

1.0

Antiarrhythmic

4/41 (9.7%)

1/19 (5.3%)

3/22 (13.6%)

0.610

Aspirin

22/41 (53.6%)

11/19 (57.9%)

11/22 (50.0%)

0.756

Calcium-channel antagonist

10/41 (24.4%)

7/19 (36.8%)

3/22 (13.6%)

0.144

Diuretic

22/41 (53.6%)

9/19 (47.4%)

13/22 (59.1%)

0.538

Statin

26/41 (63.4%)

12/19 (63.2%)

14/22 (63.6%)

1.0

  1. *Reported as median (1st; 3rd quartile) for continuous variables and count/total (percentage) for categorical variables.
  2. †Computed with unpaired Mann-Whitney U test for continuous variables and Fisher exact test for categorical variables.
Back to article page